Literature DB >> 15084636

How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?

George P Canellos, David Duggan, Jeffrey Johnson, Donna Niedzwiecki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15084636     DOI： 10.1200/JCO.2004.99.010

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.

Authors:  Jillian R Gunther; Michelle A Fanale; Jay P Reddy; Mani Akhtari; Grace L Smith; Chelsea C Pinnix; Sarah A Milgrom; Zeinab Abou Yehia; Pamela K Allen; Eleanor M Osborne; Osama Mawlawi; Bouthaina S Dabaja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-13       Impact factor: 7.038

2.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors:  Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 3.  Is BEACOPP better than ABVD?

Authors:  Bruce D Cheson
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

4.  Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.

Authors:  David J Straus; Jeffrey L Johnson; Ann S LaCasce; Nancy L Bartlett; Lale Kostakoglu; Eric D Hsi; Heiko Schöder; Nathan C Hall; Sin-Ho Jung; George P Canellos; Lawrence H Schwartz; Ronald W Takvorian; Malik E Juweid; Bruce D Cheson
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

5.  CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study.

Authors:  Jan Walewski; Elzbieta Lampka; Joanna Tajer; Włodzimierz Osiadacz; Ewa Kraszewska; Jolanta B Krzyzanowska; Janusz Meder
Journal:  Med Oncol       Date:  2009-03-25       Impact factor: 3.064

6.  The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future.

Authors:  S E Richardson; C McNamara
Journal:  Adv Hematol       Date:  2011-04-06

7.  Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis.

Authors:  Tingting Zhang; Yan Yao; Fubin Feng; Wenge Zhao; Jinhui Tian; Chao Zhou; Xue Wang; Shengjie Dong; Jia Li; Lingyu Qi; Changgang Sun
Journal:  Cancer Manag Res       Date:  2018-11-22       Impact factor: 3.989
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.